RYAH
Medtech
Inc.
Completes
Initial
Shipment
for
Major
UK-based
Clinical
Trial
TORONTO,
ON, Canada -- June 1, 2021 -- InvestorsHub NewsWire
-- RYAH Group,
Inc. (CSE:RYAH)
("RYAH"
or the "Company")
is pleased to
announce that it has completed the first
shipment of the RYAH Smart Dry Herb Inhalers which includes a delivery of
approximately 10,000 RYAH Cartridges and QR Codes to an international clinic (the
"Clinic")
undertaking
one of the
world's largest and most comprehensive clinical trials in
plant-based medicine. The initial shipment is
designated to be used by the Clinic
in a pilot run in
preparation for the
previously announced study,
based out of the United Kingdom,
on the safety and efficacy of cannabis and hemp
for the treatment of
patients suffering from chronic pain.
The
5-year study
is
expected to cover tens of thousands of
patients suffering from chronic pain, which makes it one of the
largest and most ambitious research projects to be conducted in
the
plant-based treatment
arena. Given the size and scale of the
study, RYAH has developed a custom
software solution, using OAuth API-integration to protect the
privacy of the participants in the study, with the goal of
enabling a fully integrated, patient
feedback and data collection
capability. The combination of an IoT
controlled device and direct API data integration with the
Clinic's
Electronic Health
Record (EHR) system is expected to enable scale and
mitigate
a number
of variables associated with
data collection and interpretation which are often performed
manually for both dose measurement and patient feedback.
"We are pleased
to bring RYAH's IoT device and integrated data solutions to the
United Kingdom, providing a new level of
session accuracy, patient feedback consistency, and data integrity to the
clinical framework in plant-based medicine research. We continue to
evolve our product and software
solutions to help clinicians
and
researchers
unlock breakthroughs in clinical research and analytics," said
Gregory Wagner, CEO of RYAH Group, Inc.
The medicinal
cannabis market within the United
Kingdom
keeps growing, and
by 2024 it is predicted to be worth nearly US$1.3 billion,
servicing nearly 340,000 active patients. According to a report by the
United Nation's International Narcotics
Control Board, before legalization, the U.K.
has emerged as the largest producer and
exporter of legalized cannabis for medical and research
applications.
About
RYAH Group,
Inc.
RYAH
Group,
Inc. ('RYAH')
is a connected device and big data and technology company focused
on valuable predictive analysis in the global medical plant and
nutraceutical intake industry. Its robust artificial intelligence
platform aggregates and correlates HIPAA-compliant patient data,
which is intended to help doctors and patients personalize
plant-based treatments to better predict treatment outcomes. The
data collection is relevant for clinics, doctors, dispensaries and
pharmaceutical companies and Licensed Processors (LPs) to monitor
and manage formulation effects on patient and demographics. With a
strong IP portfolio, RYAH gathers deep and insightful data on the
complete patient session and formulation lifecycle.
Forward-Looking Statements
Certain
statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may,"
"would,"
"could,"
"should,"
"potential,"
"will,"
"seek,"
"intend,"
"plan,"
"anticipate,"
"believe,"
"estimate,"
"expect" and similar expressions (or
the
negative
of these terms) are
intended to identify forward-looking information. All statements
other than statements of historical fact may be forward-looking
information. Forward-looking
statements in this press release include statements relating to
(i)
the Clinic's a pilot run and/or the previously announced study on
the safety and efficacy of cannabis and hemp for the treatment of
patients suffering from chronic pain, (ii) the projected size of
the medicinal cannabis market within the United Kingdom, and (iii)
RYAH's custom software solution, and in particular, its capacity to
protect the privacy of the participants and to enable a
fully-integrated, patient feedback and data collection capability.
Readers are further cautioned that the assumptions used in the
preparation of such forward-looking statements, including, but not
limited to, the assumption that (i)
the Company's financial condition and development plans do not
change as a result of unforeseen events, (ii) there will continue
to be a demand and market opportunity for the Company and its
subsidiaries' product offerings, and (iii) current and future
economic conditions will neither affect the business and operations
of the Company nor its ability to capitalize on anticipated
business opportunities, although considered reasonable by
management of the Company at the time of preparation, may prove to
be imprecise and result in actual results differing materially from
those anticipated, and as such, readers are
cautioned not to place undue reliance on forward-looking
statements.
Forward-looking
information reflect
the Company's current views and intentions with respect to future
events, and current information available to the Company, and are
subject to certain risks, uncertainties
and
assumptions. Many factors could cause the actual results,
performance or achievements that may be expressed or implied by
such forward-looking information to vary from those described
herein should one or more of these risks or uncertainties
materialize. These risks
include,
without limitation, risks
associated with or inherent in (i)
the
general business and economic conditions in the regions in which
the Company operates,
(ii) the
ability of the Company and its
subsidiaries to execute
on key priorities (including
completion of acquisitions and strategic plans,
and
the
retention of key
executives), (iii)
the ability of the Company to integrate newly
acquired businesses,
(iv) the
expected
benefits
of RYAH's user-generated, HIPAA-compliant data,
and the
anticipated results
and
experience of users may
receive from using RYAH products, (v)
the
Company's
ability to
implement business strategies and pursue business
opportunities,
(vi) disruptions
in or attacks (including cyber-attacks) on the Company's
information technology, internet, network access or other voice or
data communications systems or services,
(vii) the
evolution of various types of fraud or other criminal behavior to
which the Company is exposed,
(viii) the
failure of third parties to comply with their obligations to the
Company or its affiliates,
(ix) changes
to, or the
application
of, laws and regulations legal and
regulatory risks inherent in the cannabis industry, and
(x) cannabis-related
products
manufactured for human consumption (including
potential product recalls).
Should
any such
factor
affect the Company in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect, the
actual results or events may differ materially from the results or
events predicted. The forward-looking information included in this
press release is made as of the date of this press release,
and
is
expressly qualified in its entirety by this cautionary statement.
The Company
undertakes no obligation to publicly update or revise any
forward-looking information, other than as required by applicable
law.
This press
release includes market and industry data that has been obtained
from third party sources, including industry publications. The
Company believes that the industry data is accurate and that its
estimates and assumptions are reasonable, but there is no assurance
as to the accuracy or completeness of this data. Third party
sources generally state that the information contained therein has
been obtained from sources believed to be reliable, but there is no
assurance as to the accuracy or completeness of included
information. Although the data is believed to be reliable, the
Company has not independently verified any of the data from third
party sources referred to in this press release or ascertained the
underlying economic assumptions relied upon by such
sources.
RYAH
Medtech
Inc.
Contacts:
Sofiya Kleshchuk
Client Relations
+1 917 210 0543
Invest@ryahgroup.com
Gregory Wagner, CEO
917 210
0543
Info@ryah.com
Corporate Communications:
InvestorBrandNetwork
(IBN)
Los
Angeles, California
www.InvestorBrandNetwork.com
310.299.1717
Office
Editor@InvestorBrandNetwork.com